For Patients

A NEW STANDARD OF CARE

Pathologic grading is subjective in treatment planning

Fifty percent of patient tumors are categorized grade 2, forcing oncologists to rely on further testing. But large percentages of patients with grade 2 and 3 tumors are eventually discovered to be low risk of recurrence and could have been spared the time and costs of gene expression testing.

LEARN MORE, FASTER.

Faster tumor analysis means a quicker path to care

PreciseBreast™ offers a faster, less expensive alternative to gene expression testing for predicting the risk of recurrence.

1. Mahtani, R. L. 2024. PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospectivestudy of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc. [Poster]. SABCS, Dec. 9, 2024, San Antonio, TX.

The Underlying Problem

Tumor grading can be subjective, and further analysis can be time consuming and expensive

Traditional tumor grading in breast cancer can be subjective, resulting in a high percentage of patients being classified with Intermediate/Grade 2 tumors even though many are low risk. As a result, patients must wait 2-6 weeks for costly gene expression test results, ultimately delaying vital care planning.

50%

of breast tumors are categorized as Grade 2*

65%

Intra-observer variations in grading results***

56%

of Grade 3 tumors are low risk**

22%

of Grade 2 tumors are high risk**

78%

of Grade 2 tumors are low risk**

1 in 8 women will be diagnosed with breast cancer in their lifetime.

*Sparano, New England Journal of Medicine. 2018
**Based on a retrospective longitudinal study of more than 2,000 cancer cases. Fernandez, G., Prastawa, M., Madduri, A.S. et al. Breast Cancer Research 2022’.
***Paik, New England Journal of Medicine, 2004

Precision matters

Using PreciseBreast^TM as well as gene expression or visual pathologic analysis delivers benefits for patients, physicians, and payors.

Data to drive precise reporting of tumor recurrence risk

Faster results lessen anxiety for patients

Lower overall costs for treatment and testing

Availability to 100% of eligible patients

our process

The clinical pathway

PreciseBreast is designed specifically to improve the multidisciplinary team’s workflow, providing a complement to pathological tumor grading and gene expression testing.

Screening / Detection

Biopsy & Diagnosis

Resection

Tumor Grading

Tumor Staging

Gene-Expression Testing

Care Planning

who we serve

PreciseStories

The results of slow or unavailable gene-expression testing can impact patients and their anxiety levels during a critical time in their lives. These are their stories of how PreciseBreast might have made a difference.